bluuebunny/crossref_metadata_2025_split huggingface dataset:
295 Impacts of travel distance and travel direction on back-to-back games in the National Basketball Association (NBA)
Authors: Charest Jonathan , Samuels Charles , Bastien Célyne , Lawson Doug , Grandner Michael 
Published: May 2021

Abstract

Introduction
Travel fatigue and circadian disruptions are known factors that can hinder performance in professional athletes. The present exploratory study focused on investigating the impact of travel distance and direction on back-to-back games over the 2013–2020 seasons in the National Basketball Association (NBA).

Methods
Data from away and home games of back-to-back sequences, in two different cities, from the 2013 to 2020 seasons in the National Basketball Association were included in this study. Information from every selected game was retrieved from the official website of the NBA (www.nba.com). The outcomes were based on winning percentage with additional covariates including the direction of travel (eastward or westward) and the distance travelled (0-500km – 501-1000km – 1001-1500km – 1501km and more). If a team played both games of a back-to-back sequence on the road, they were considered Away-Away; if a team played the first game of a back-to-back sequence at home they were considered Home-Away; if a team played the first game of a back-to-back sequence on the road they were considered Away-Home.

Results
The sequence Away-Home significantly increases the likelihood of winning compared to the Away-Away and Home-Away sequences 54.4% (95%CI: 54.4,54.5); 39.2% (95%CI: 37.2,41.2), and 36.8%, (95%CI: 36.7,36.8), respectively. Following a road game, when teams travel back home, every additional 500km reduces the likelihood of winning by approximately 4% (p = 0.038). Finally, after withdrawing the Away-Home sequence, travelling eastward significantly increases the chance of winning (p = 0.024) compared to westward travel but has no significant impact on the probability of winning compared to neutral time zone travel (p = 0.091).

Conclusion
The accumulation of travel fatigue and the chronic circadian desynchronization that occurs over the NBA season can acutely disturb sleep and recovery. It appears that tailored sleep and recovery strategies need to be dynamically developed throughout the season to overcome the different challenges of the NBA schedule.
Support (if any):
297 The Relationship Between Sleep and Objectively Measured Sedentary Behavior in Adults with Desk Jobs
Authors: Egeler Mara , Kubala Andrew , Perera Subashan , Patel Sanjay , Hall Martica , Jakicic John , Gibbs Bethany Barone , Kline Christopher 
Published: May 2021

Abstract

Introduction
Both poor sleep and sedentary behavior lead to negative health outcomes. While some previous studies have observed an association between poor sleep and greater sedentary behavior, few studies have assessed this relationship using an objective measure of sedentary behavior. We examined the association of both self-reported and objectively-measured sleep with objectively-measured sedentary behavior.

Methods
In a secondary analysis of baseline data from an ongoing clinical trial, the present analysis included 157 physically inactive adults with elevated blood pressure (120–159 mmHg systolic or 90–99 diastolic) and desk jobs (82.8% white, 65.6% female, age 45.5±12.0). To assess sedentary behavior, participants wore an accelerometer/inclinometer (activPAL3 micro) on the upper thigh continuously for 7 days. Variables included total sedentary time, prolonged sedentary time (≥30 minute bouts), and sit-to-stand transitions; these were averaged across all waking hours as well as the workday. To assess sleep, participants completed the Pittsburgh Sleep Quality Index (PSQI) and a subsample (n=57) wore an Actiwatch Spectrum for 7 nights. Variables examined included the PSQI global score, actigraphy-based total sleep time (TST) and sleep efficiency (SE). Linear regression examined associations between sleep and sedentary behavior, with adjustments for age, gender, race, body mass index, and activPAL3 wear time.

Results
Participants had (mean±standard deviation) 11.1±1.5 hours sedentary time per day, with 6.3±2.0 occurring in ≥30 minute bouts, and 51.3±13.4 sit-to-stand transitions. During the workday, participants had 6.6±1.3 hours sedentary time with 3.8±1.7 occurring in ≥30 minute bouts and 27.2±11.2 sit-to-stand transitions. PSQI global score was 4.9±2.9; 32.5% were classified as poor sleepers. Actigraphic TST was 6.7±0.8 hours, with SE of 85.4±6.3%.Greater SE was associated with less sit-to-stand transitions during the workday (β=-0.36, p=0.01) and during the full day (β=-0.37, p=0.01). Subjective sleep quality and actigraphic TST were not associated with sedentary behavior.

Conclusion
We did not find a cross-sectional association between sedentary behavior and sleep in insufficiently active adults, potentially due to restricted range of sedentary behavior and physical activity in the sample. The association between greater sleep efficiency with fewer sit-to-stand transitions is counterintuitive and warrants further exploration.

Support (if any)
This study was funded by National Institutes of Health (NIH) grants R01HL134809 and R01HL147610.
300 The Use of Sleep Aids in Young Athletes and Non-Athletes: An Exploratory Study
Authors: Caron Jean-François , Godin Roxanne , Gaudreault Pascale , Roy Jonathan , Forest Geneviève 
Published: May 2021

Abstract

Introduction
Studies have shown that sleep in adolescents is characterized by sleep disturbances. Many teens resort to prescribed or nonprescribed medication to alleviate their sleep difficulties. Research suggests that sport and physical activity may be protective factors regarding sleep. The aims of the present study were to investigate the use of sleep aids among young athletes and non-athletes, and to identify possible factors associated with prescribed and nonprescribed sleep aids

Methods
35 young athletes (14.6±0.7 years old; 54.3 % males) and 30 young non-athletes (15.1±0.7 years old; 16.7% males) completed questions on sleep aids, the Academic Motivation Scale, the anxiety and depression scales of the Beck Youth Inventory-II, and the Multidimensional Self-Esteem Questionnaire, at the beginning, middle, and end of the school year. Mean scores for the school year were computed for amotivation in school, intrinsic academic motivation of accomplishment, self-esteem, anxiety symptoms, and depressive symptoms. Teens were each categorized as user or non-user if they had or had not used sleep aids during the school year. First, comparison of sleep aids usage between groups were done using a Chi-square test. Then, both groups of athletes and non-athletes were combined. Amotivation, intrinsic motivation, self-esteem, and anxiety and depressive symptoms were compared between users and non-users using paired t-tests

Results
Results show that young non-athletes report using sleep aids more often than young athletes (X2(1,N=65)=5.205, p=.023). Indeed, 65.2% non-athletes compared to 34.8% athletes reported using sleep aids during school year. Users represent 35.4% of the total sample. T-tests showed that users have a significantly higher amotivation score (t(65)=-2.010, p=.049), more anxiety symptoms (t(65)=-2,480, p=.016), and more depressive symptoms (t(65)=-2,126, p=.037) than non-users.

Conclusion
These results show a high prevalence of prescribed and nonprescribed sleep aids usage in teens. Our results also suggest that sleep aids in young adolescents is associated with mental health problems and academic motivation issues. On the other hand, our results support that sport and physical activity may have a protective role regarding sleep. This highlights the importance to promote sport participation among adolescents.

Support (if any)
n/a
305 Subjective sleep predicts Cadet performance during U.S. Army Reserve Officer Training Corps Advanced Camp
Authors: Carlsson Kajsa , Mickelson Carolyn , Choynowski Jake , Mantua Janna , Devine Jaime , Sowden Walter , Mckeon Ashlee 
Published: May 2021

Abstract

Introduction
U.S. Army Reserve Officer Training Corps (ROTC) Advanced Camp (AC) is a 29-day training that assesses military skills and leadership potential in college students training to become Commissioned Officers (i.e. Cadets). Military trainings are widely known to disrupt normative sleep. Additionally, operational sleep disruption is linked to performance decrements. This study examined the ability for objective and subjective sleep during ROTC AC to predict Cadet performance.

Methods
One hundred and fifty-nine ROTC Cadets (age 22.06±2.49 years; 76.1% male) wore an actiwatch device continuously for 29 days during AC. Paper surveys administered at the end of AC captured subjective sleep metrics during the training. ROTC instructors evaluated Cadet performance and provided scores of overall class rank and summary performance. Multiple and ordinal linear regressions assessed the predicative utility of subjective (sleep duration [SD]; Global score [Global] from the Pittsburgh Sleep Quality Index) and objective (Total Sleep Time [TST]; Sleep Efficiency [SE]; Sleep Latency Onset [SOL]; Wake After Sleep Onset [WASO] from actigraphy) sleep on performance.

Results
The interaction of SD and Global, when controlling for age and gender, significantly predicted increased Cadet rank, F(4,153) = 3.09, p = 0.018. Models testing the prediction of SD and Global on summary performance score were non-significant. Further, regressing of both Cadet rank and summary performance individually on objective sleep metrics, when controlling for age and gender, resulted in non-significant findings.

Conclusion
Subjective and objective sleep showed no significant individual predictive utility on performance. However, the combined subjective model significantly predicted that Cadets who slept worse (lower SD; higher Global) during AC received a lower rank at the end of the training. These findings suggest there may be a unique combined predictive utility of subjective sleep on performance when compared to the predictive power of individual variables. Therefore, subjective sleep may be better for predicting operational performance than objective sleep. Future analyses will refine these models and examine how performance on individual AC events may be influenced by sleep. Support for this study came from the Military Operational Medicine Research Program (MOMRP) of the United States Army Medical Research and Development Command (USAMRDC).
Support (if any):
324 Naturalistic Characterization of Sleep in Chronic Insomnia Using a Non-Contact Sleep Measurement Device
Authors: Hansen Devon , Peterson Mary , Raymann Roy , Van Dongen Hans , Watson Nathaniel 
Published: May 2021

Abstract

Introduction
Individuals with insomnia report poor sleep quality and non-restorative sleep, and often exhibit irregular sleep patterns over days and weeks. First night effects and logistical challenges make it difficult to measure these sleep characteristics in the laboratory. Also, sensitivity to sleep disruption from obtrusive measurement devices confounds sleep measurements in people with insomnia in their naturalistic setting. Non-contact sleep measurement devices have the potential to address these issues and enable ecologically valid, longitudinal characterization of sleep in individuals with insomnia. Here we use a non-contact device – the SleepScore Max (SleepScore Labs) – to assess the sleep of individuals with chronic insomnia, compared to healthy sleeper controls, in their home setting.

Methods
As part of a larger study, 13 individuals with chronic insomnia (ages 25-60y, 7 males) and 8 healthy sleeper controls (ages 21-46y, 6 females) participated in an at-home sleep monitoring study. Enrollment criteria included an age range of 18-65y and, for the insomnia group, ICSD-3 criteria for chronic insomnia with no other clinically relevant illness. Participants used the non-contact sleep measurement device to record their sleep periods each night for 8 weeks. Sleep measurements were analyzed for group differences in both means (characterizing sleep overall) and within-subject standard deviations (characterizing sleep variability across nights), using mixed-effects regression controlling for systematic between-subject differences.

Results
Based on the non-contact sleep measurements, individuals with chronic insomnia exhibited greater variability in bedtime, time in bed, total sleep time, sleep latency, total wake time across time in bed, wakefulness after sleep onset, sleep interruptions, and estimated light sleep, compared to healthy sleeper controls (all F&gt;5.7, P&lt;0.05). No significant differences were found for group averages and for variability in estimated deep and REM sleep.

Conclusion
In this group of individuals with chronic insomnia, a non-contact device used to characterize sleep naturalistically captured enhanced variability across nights in multiple aspects of sleep stereotypical of sleep disturbances in chronic insomnia, differentiating the sample statistically significantly from healthy sleeper controls.

Support (if any)
NIH grant KL2TR002317; research devices provided by SleepScore Labs.
337 A Multicenter Open-label Pilot Study Evaluating Next-Dose Transition From Zolpidem to Lemborexant: Analysis of Female Subgroup
Authors: Ahmad Maha , Malhotra Manoj , Amchin Jess , Kumar Dinesh , Perdomo Carlos , Atkins Norman , Moline Margaret 
Published: May 2021

Abstract

Introduction
Dosing paradigms for transitioning patients to lemborexant (LEM) from zolpidem (ZOL: immediate [IR] or extended-release [ER]) were examined in E2006-A001-312 (Study 312; NCT04009577), an open-label pilot study. Given insomnia prevalence in women, post hoc analyses in female subjects were conducted.

Methods
Study 312 included: 3-week Screening Period (subjects continued ZOL); 2-week Titration Period (TITR); 12-week Extension Period (EXT); 4-week Follow-up. Adults with insomnia taking ZOL-IR or ZOL-ER intermittently (3–4 nights/week) or frequently (≥5 nights/week) were enrolled. Subjects with intermittent, or one week each of intermittent and frequent ZOL use, were assigned to Cohort-1 and started TITR with LEM 5mg (LEM5). Frequent ZOL users (Cohort-2) were randomized 1:1 to LEM5 (Cohort-2A) or LEM 10mg (LEM10; Cohort-2B). Subjects who transitioned to LEM could opt into EXT. Subjects could change LEM dose during TITR (only once) and during EXT. The primary endpoint was the proportion of subjects who transitioned to LEM at end of TITR. Treatment-emergent adverse events (TEAEs) were assessed by dose at time of TEAE.

Results
Overall, 35 subjects were female and 29/35 (82.9%) transitioned to LEM. In Cohort-1, 7 subjects began TITR; all transitioned to LEM (5 subjects ended TITR on LEM5; 2 ended on LEM10). In Cohort-2A, 14 subjects began TITR with LEM5; 12/14 (85.7%) transitioned (6 subjects each ended TITR on LEM5 or LEM10). In Cohort-2B, 14 subjects began TITR with LEM10; 10/14 (71.4%) transitioned to LEM (3 subjects ended TITR on LEM5 and 7 on LEM10). All 29 transitioned subjects opted into EXT, and 27/29 (93.1%) completed the study. Based on modal dose (most frequent dose taken during TITR and EXT combined) groups, median time to first dose change during EXT was 14.5 and 17.0 days for LEM5 and LEM10, respectively. Overall, most TEAEs were mild/moderate in severity. Across TITR and EXT, more TEAEs occurred with LEM10 than with LEM5; the most common TEAEs were somnolence (n=3) and abnormal dreams (n=3).

Conclusion
Most female subjects successfully transitioned from intermittent or frequent ZOL-IR/ZOL-ER use to LEM and completed the study. LEM was generally well tolerated. The safety profile was consistent with that observed in Phase 3 studies.

Support (if any)
Eisai Inc.
343 A benefit-risk assessment of daridorexant for the treatment of insomnia using patient preference data from two phase 3 trials
Authors: Heidenreich Sebastian , Phillips-Beyer Andrea , Ross Melissa , Chua Gin Nie , Fietze Ingo , Mayleben David 
Published: May 2021

Abstract

Introduction
The efficacy and safety of daridorexant, a dual orexin receptor antagonist intended to treat insomnia, was demonstrated in two placebo-controlled phase III trials. Both pivotal trials included instruments for eliciting treatment preferences of enrolled patients, to interpret the trial findings from their perspective using a patient-centered benefit-risk assessment (pBRA).

Methods
Digital ethnographies and qualitative interviews with insomnia patients informed the design of a discrete choice experiment (DCE). The DCE was pre-tested in qualitative and quantitative pilots before inclusion in the trials. Within the DCE, patients were asked to make trade-offs between seven outcomes (“time to fall asleep,” “total time asleep,” “daytime functioning,” “likelihood of daytime dizziness/grogginess,” “likelihood of abnormal thoughts and behavioural changes,” “likelihood of falls in the night,” and “treatment withdrawal”). The preference data were analysed using a mixed logit (MXL) model that accounted for preference heterogeneity. Relative attribute importance (RAI) and maximum acceptable risk (MAR) of abnormal thoughts and behavioral changes were obtained from the MXL. A pBRA combined elicited preferences with collected clinical trial data to predict preferences for daridorexant over placebo. Sensitivity analysis accounted for uncertainty in both clinical outcomes and preferences.

Results
Patients valued all seven outcomes (p &lt; 0.05), but considered improving daytime functioning (RAI = 33.7%) and avoiding treatment withdrawal (RAI = 27.5%) as most important. Patients were also willing to accept an additional 18.8% risk (p-value &lt; 0.001) of abnormal thoughts and behavioral changes for an improvement in daytime functioning from difficulty functioning to restricted functioning. The pBRA suggested that both daridorexant 50 mg and 25 mg were significantly preferred (p-value &lt; 0.001) over placebo, and 50 mg was significantly preferred (p-value &lt; 0.001) over 25 mg, even after accounting for uncertainty in clinical outcomes and preferences.

Conclusion
All seven outcomes included in the DCE were valued by patients, but improving daytime functioning and avoiding severe treatment withdrawal was considered as most important. Daridorexant 50 mg and 25 mg were found to be significantly preferred over placebo, suggesting a positive benefit-risk balance of both doses. Overall, the preference data allowed for an innovative interpretation of the trial data from patients’ perspective.
Support (if any):
345 Preliminary efficacy of CBT-I for psychosis in a Veteran sample
Authors: Howell Mary Katherine , Klingaman Elizabeth A 
Published: May 2021

Abstract

Introduction
Sleep dysfunction is pervasive in people with psychosis. Insomnia worsens psychotic symptoms and functioning, though treating insomnia can improve functioning. Cognitive Behavioral Therapy for Insomnia (CBT-I) is an effective treatment, but there has been limited research on CBT-I in persons with psychosis. There is mounting evidence that sleep disturbances in people with psychiatric disorders do not improve with treatment of psychiatric illness. The present study 1) developed empirical guidelines for tailoring CBT-I to the needs of people with psychosis and insomnia; 2) conducted a preliminary efficacy study of CBT-I with these novel guidelines for psychosis; and 3) utilized objective and subjective insomnia and functional measures.

Methods
Novel psychosis guidelines were developed in response to illness-related, environmental, and practical challenges for engaging in traditional components of CBT-I, identified via a series of 25 qualitative interviews and an uncontrolled acceptability trial. A preliminary efficacy study of CBT-I with novel psychosis guidelines was conducted against an active treatment comparison group. Forty-seven Veterans with insomnia and co-occurring psychotic-spectrum disorder completed sleep measures, including the Insomnia Severity Index (ISI), at baseline, post-treatment, and 3-month follow-up.

Results
Psychosis guidelines for CBT-I included supporting integrated care (e.g., with case managers, prescribers, etc.), simplifying instructions on all treatment materials, reminder handouts, reality testing with sleep-related experiences, cognitive restructuring guidance for common sleep-related cognitions held by people with psychosis, techniques for use during psychotic experiences at bedtime. At post-treatment and follow-up, there was a large effect of CBT-I on ISI scores (d = 1.00, 1.18, respectively). Further, a clinically significant reduction in mean ISI score of participants was observed in the CBT-I condition (&gt; 6), but not in the control condition. Participants in the CBT-I group reported reductions in daily functional impairment due to sleep problems (from 89% to 50%), while the control group reported a slight increase in functional impairment (from 86% to 88%).

Conclusion
CBT-I delivered with guidelines for psychosis should be further investigated with a larger randomized controlled trial over a longer time period of 6 months.

Support (if any)
Time on this project was supported by the U.S. Department of Veterans Affairs, Rehabilitation Research and Development Service-1IK2RX001836, PI: Elizabeth A. Klingaman.
348 Absence of Withdrawal Symptoms and Rebound Insomnia Upon Discontinuation of Daridorexant in Patients with Insomnia
Authors: Leger Damien , Fietze Ingo , Pain Scott , Kinter Dalma Seboek , Flamion Bruno , Mignot Emmanuel 
Published: May 2021

Abstract

Introduction
Abrupt discontinuation of sleep medications in patients with insomnia often causes withdrawal symptoms and rebound insomnia. In a Phase 3 program evaluating efficacy and safety of daridorexant on sleep and daytime functioning in patients with insomnia during 3 months of treatment, the risks of withdrawal symptoms and rebound insomnia were evaluated at treatment cessation.

Methods
In two randomized, double-blind, 3-month trials, adult (18–64 years) and elderly (≥65) patients with insomnia were assigned (1:1:1) to receive oral daridorexant 25mg, 50mg or placebo (Trial-1, NCT03545191) or 10mg, 25mg or placebo (Trial-2, NCT03575104) every evening. Each trial included a 7-day, single-blind, placebo run-out period following double-blind treatment to evaluate withdrawal symptoms and rebound insomnia. Withdrawal effects were assessed by the change in Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ) total score, from last assessment on double-blind treatment to end of placebo run-out, and occurrence of relevant adverse events (AEs). Rebound insomnia was assessed objectively by change in wake-after-sleep-onset (WASO) and latency-to-persistent sleep (LPS), from baseline to first night of placebo run-out, and by subjective total-sleep-time (sTST), from baseline to end of run-out (mean of 7-days). Analyses included all patients who received ≥1 dose of placebo run-out treatment (Trial-1: N=852; Trial-2: N=851).

Results
No increase in mean BSWQ score from last assessment on double-blind treatment to end of placebo run-out was reported (Trial-1: 25mg, -0.6±2.3; 50mg, -0.6±2.3; placebo, -0.7±2.3; Trial-2: 10mg, -0.5±2.6; 25mg, -0.4±1.9; placebo, -0.4±1.4). No patients had a BWSQ score &gt;20 at end of run-out. No AEs suggestive of withdrawal symptoms were reported. Mean WASO and LPS values (min) decreased from baseline to placebo run-out (WASO Trial-1: 25mg, -8.6±55.5; 50mg, -2.5±52.4; placebo, -20.4±45.8; Trial-2: 10mg, -11.6±58.3; 25mg, -5.1±57.9; placebo, -26.2±53.5; LPS Trial-1: 25mg, -17.2±56.7; 50mg, -15.0±55.8; placebo, -27.8±47.2; Trial-2: 10mg, -17.3±67.2; 25mg, -10.3±67.3; placebo, -18.3±63.8) while sTST values (min) increased (Trial-1: 25mg, 43.3±53.8; 50mg, 42.9±59.6; placebo, 42.3±52.7; Trial-2: 10mg, 43.3±52.9; 25mg, 46.8±55.4; placebo, 42.3±53.8) indicating absence of rebound effects.

Conclusion
Treatment with daridorexant for up to 3-months was not associated with any evidence of drug withdrawal or rebound insomnia upon abrupt discontinuation, indicating no safety concerns for patients should treatment be stopped.

Support (if any)
Funded by Idorsia Pharmaceuticals Ltd.